SillaJen IPO Part 3 - Competitive Strengths of Product (Pexa-Vec)
* In Part 3 (as below), I summarized the competitive strengths of product (Pexa-Vec).SillaJen's Pexa-Vec is an advanced liver cancer treatment...
339 Views
Long Position with Upcoming Catalysts
We expect the complete response letter (CRL) for Andexanet Alfa to be resolved in 2017 and the drug to be launched successfully in the U.S. market....
496 Views
Lupin Ltd.: Another Undervalued Generic Drugs Powerhouse
The common stock could be worth Rs. 1874 at 25x FY2018 consensus EPS estimate (33% potential upside). Using both forward EV/EBITDA and forward P/E...
449 Views
Election Winners and Losers
President-elect Donald Trump's impact on most companies' intrinsic value is expected to be immaterial, even with a Republican-controlled Congress....
209 Views
Five More Actionable Ideas in a Post-Trump World
Summary: These include: Short U.S. treasury bonds, short emerging markets (but long Russia equity index), long U.S. dollar and short Euro. Apart...
297 Views